Trial · NCT04317040
Results by group61
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 61
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status | CD24Fc | 6.0 | 95% Confidence Interval 5.0 to 9.0 | Days | |
| Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status | Placebo | 10.5 | 95% Confidence Interval 7.0 to 15.0 | Days | |
| Number of Participants Who Experience an Adverse Event (AE) | CD24Fc | 32 | Participants | ||
| Number of Participants Who Experience an Adverse Event (AE) | Placebo | 35 | Participants | ||
| Percentage of Participants Who Died or Had Respiratory Failure (RF) | CD24Fc | 22.4 | Percentage of Participants | ||
| Percentage of Participants Who Died or Had Respiratory Failure (RF) | Placebo | 28.0 | Percentage of Participants | ||
| Time to Disease Progression in Clinical Status of COVID-19 | CD24Fc | NA | 95% Confidence Interval NA to NA | Days | |
| Time to Disease Progression in Clinical Status of COVID-19 | Placebo | NA | 95% Confidence Interval NA to NA | Days | |
| Number of Participants Who Died Due to Any Cause | CD24Fc | Day 15 | 11 | Participants | |
| Number of Participants Who Died Due to Any Cause | Placebo | Day 15 | 8 | Participants | |
| Number of Participants Who Died Due to Any Cause | CD24Fc | Day 29 | 16 | Participants | |
| Number of Participants Who Died Due to Any Cause | Placebo | Day 29 | 18 | Participants | |
| Rate of Clinical Relapse | CD24Fc | 4.3 | 95% Confidence Interval 1.41 to 9.77 | Percentage of Participants | |
| Rate of Clinical Relapse | Placebo | 6.8 | 95% Confidence Interval 2.97 to 12.92 | Percentage of Participants | |
| Conversion Rate of COVID-19 Clinical Status | CD24Fc | Day 8 | 55.2 | 95% Confidence Interval 45.7 to 64.4 | Percentage of participants |
| Conversion Rate of COVID-19 Clinical Status | Placebo | Day 8 | 42.4 | 95% Confidence Interval 33.3 to 51.8 | Percentage of participants |
| Conversion Rate of COVID-19 Clinical Status | CD24Fc | Day 15 | 71.6 | 95% Confidence Interval 62.4 to 79.5 | Percentage of participants |
| Conversion Rate of COVID-19 Clinical Status | Placebo | Day 15 | 55.9 | 95% Confidence Interval 46.5 to 65.1 | Percentage of participants |
| Time to Hospital Discharge | CD24Fc | 7.0 | 95% Confidence Interval 6.0 to 9.0 | Days | |
| Time to Hospital Discharge | Placebo | 10.5 | 95% Confidence Interval 7.0 to 15.0 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04317040/results